delphi process (Surface Oncology)
86
Structured Review
Surface Oncology
delphi process
Delphi Process, supplied by Surface Oncology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/delphi/delphi+process/pm42277799-286-39-33
Average 86 stars, based on 1 article reviews
Delphi Process, supplied by Surface Oncology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/delphi/delphi+process/pm42277799-286-39-33
Average 86 stars, based on 1 article reviews
delphi process - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Modification:Article Title: Defining a 'cells to society' research framework for appendiceal tumours. Article Snippet: Tumours of the appendix — a vestigial digestive organ attached to the colon — are rare.. Although we estimate that around 3,000 new appendiceal cancer cases are diagnosed annually in the USA, the challenges of accurately diagnosing and identifying this tumour type suggest that this number may underestimate true population incidence.. In the current absence of disease-specific screening and diagnostic imaging modalities, or well-established risk factors, the incidental discovery of appendix tumours is often prompted by acute presentations mimicking appendicitis or when the tumour has already spread into the abdominal cavity — wherein the potential misclassification of appendiceal tumours as malignancies of the colon and ovaries also increases. Article Title: Insights into the Clinical Prognosis of High-grade Appendiceal Mucinous Neoplasms Article Snippet: High-grade appendiceal mucinous neoplasm (HAMN) is used to describe a rare epithelial neoplasm of the appendix characterized by pushing-type invasion and high-grade cytologic atypia.. Its implications regarding lymph node spread and the necessity of right colectomy are currently debate.. The objective of the present study was to assess the clinicopathologic characteristics, the risk of lymph node and peritoneal metastasis, and long-term outcomes of patients diagnosed as HAMN in comparison to low-grade appendiceal mucinous neoplasm (LAMN) and appendiceal adenocarcinoma, treated by right hemicolectomy. Article Title: Prognosis conferred by molecular features of appendix-derived Pseudomyxoma Peritonei. Article Snippet: Introduction: Pseudomyxoma Peritonei (PMP) is an extremely rare disease characterized by progressive accumulation of mucinous ascites and implants in the peritoneum.. We investigated the prognostic value for response to cytoreductive surgery (CRS) or hyperthermic intraperitoneal chemotherapy (HIPEC) and dissected potential beneficial targeted therapy utilizing genomic characteristics.. Methods: Whole-exome sequencing (WES) was performed on tissue specimens and matched white blood cells from 81 patients with PMP. Article Title: Treatment and Management of Peritoneal Spread from Appendiceal Neoplasms. Article Snippet: Appendiceal neoplasms are rare and account for less than 1% of all cancers and have been noted in 1% to 1.5% of appendectomy specimens.. When not found incidentally on imaging, these neoplasms are known to frequently mimic appendicitis or cause abdominal discomfort due to large volume mucinous ascites.. The malignant potential is variable and dependent on the histologic characteristics of the tumor. Article Title: Presentation Patterns and Treatment Outcomes in Appendix Cancer Patients Traveling to a High-Volume Peritoneal Surface Malignancy Center. Article Snippet: Introduction: Mucinous appendix cancer (MAC) treatment is centralized at peritoneal surface malignancy centers (PSMCs), requiring patients to travel for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).. We compared presentation patterns and outcomes for patients accessing a high-volume PSMC from in-state (I-S) vs out-of-state (O-S).. Methods: This cohort study of MAC patients with peritoneal metastases treated with CRS/HIPEC (1998-2023) used a prospective database. Article Title: Postoperative follow-up compliance and survival analysis in pseudomyxoma peritonei patients treated with CRS and HIPEC: a six-year retrospective study. Article Snippet: .. Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, et al. A Consensus for classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Article Title: Prognostic value of preoperative serum C-reactive protein level for survival in mucinous appendix cancer treated with complete CRS/HIPEC. Article Snippet: Background: The role of systemic inflammation, a significant prognostic factor in various malignancies, is underexplored in mucinous appendix cancer (MAC).. We assessed how inflammation, expressed by preoperative serum C-reactive protein (CRP), correlates with survival across MAC histopathologies managed with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).. Methods: This retrospective cohort study included MAC patients with peritoneal dissemination, who had complete CRS/HIPEC (CC-0/1) (1998–2023). Histopathology:Article Title: Presentation Patterns and Treatment Outcomes in Appendix Cancer Patients Traveling to a High-Volume Peritoneal Surface Malignancy Center. Article Snippet: Introduction: Mucinous appendix cancer (MAC) treatment is centralized at peritoneal surface malignancy centers (PSMCs), requiring patients to travel for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).. We compared presentation patterns and outcomes for patients accessing a high-volume PSMC from in-state (I-S) vs out-of-state (O-S).. Methods: This cohort study of MAC patients with peritoneal metastases treated with CRS/HIPEC (1998-2023) used a prospective database. Article Title: Prognostic value of preoperative serum C-reactive protein level for survival in mucinous appendix cancer treated with complete CRS/HIPEC. Article Snippet: Background: The role of systemic inflammation, a significant prognostic factor in various malignancies, is underexplored in mucinous appendix cancer (MAC).. We assessed how inflammation, expressed by preoperative serum C-reactive protein (CRP), correlates with survival across MAC histopathologies managed with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).. Methods: This retrospective cohort study included MAC patients with peritoneal dissemination, who had complete CRS/HIPEC (CC-0/1) (1998–2023). |